Akt is a serine/threonine kinase mediating multiple intracellular pathways involved in prostate cancer (CaP) biology. Increased understanding of the molecular mechanisms of Akt activation and signaling have led to the development of an increasing number of Akt inhibitors. These biologic agents demonstrate activity against a wide range of cancers in preclinical studies. Clinical studies of Akt inhibition in CaP are in progress, including agents such as celecoxib, perifosine and genistein. How best to integrate Akt inhibitors with standard CaP therapy or select patients most likely to benefit is the subject of ongoing research.
Introduction
Akt, or protein kinase B, is a serine/threonine kinase that plays an important role in intracellular signaling cascades. A variety of neoplasms show perturbations in the biochemical pathways affected by Akt. Prostate cancer (CaP) specifically shows biochemical abnormalities related to Akt that may be of importance in sustaining tumor growth by preventing apoptosis and promoting proliferation and angiogenesis.
CaP is the most common noncutaneous malignancy in American males and is predicted to be the third leading cause of cancer deaths for 2006. 1 While local therapy for CaP is relatively effective, androgen deprivation therapy remains the mainstay of treatment for disseminated disease and is principally palliative in nature. Introduced in the 1940s, 2 androgen deprivation removes androgen stimulation, initially inducing apoptosis in CaP. However, the disease eventually progresses to an androgen independent (AI) state with an associated life expectancy of only 15-20 months. Androgen deprivation, while extending length and quality of life for many patients, also induces tumor-specific biochemical changes of many intracellular factors including Akt. These changes may promote progression to an AI state. 3 Novel treatments for AI CaP are needed. Increasing understanding of the many biochemical changes associated with neoplastic progression and androgen independence has led to the identification of novel targets for therapeutic intervention. In this review, we discuss pathways relating directly to Akt, focusing on those showing the greatest relevance to current and possible future therapeutic strategies.
Pathways affected by Akt

Akt form and function
Akt was originally identified as an oncogene within the AKT8 retrovirus. This retrovirus was isolated from the AKR strain of mice that have a high incidence of leukemia and lymphoma. 4 Subsequent genetic analysis demonstrated that Akt is an important intracellular signaling moiety highly conserved across species. A member of the AGC kinase family, it is very similar to protein kinase A and protein kinase C. When first discovered, it was therefore named 'protein kinase B' and is sometimes called RAC (related to A and C).
In humans, Akt is a family of three homologous members out of which Akt1 and Akt2 are more widely distributed than Akt3. 5 Akt has three domains with specific functions. The N-terminal domain is a pleckstrin homology (PH) domain, which can bind phosphoinositides (PI) in the cellular membrane. The C-terminal domain is a regulatory domain and the central portion of the protein is the catalytic domain. 6 Complete activation of the catalytic activity of Akt requires phosphorylation of a threonine residue at 308 and a serine residue at 473. It is possible that Akt shows partial activation with phosphorylation at the threonine 308 position. 7 
Akt activation
Akt activation occurs in response to multiple extracellular signals acting through tyrosine kinase and Gprotein coupled receptors (see Figure 1 ). These receptor types activate phosphoinositol-3-kinase (PI3K) class IA and IB, respectively. In turn, PI3K phosphorylates the membrane phospholipid, phosphatidylinositol-4,5-bisphosphonate (PI(4,5)P 2 ), which then acts as the secondmessenger phosphatidylinositol-3,4,5-trisphosphonate (PI(3,4,5)P 3 ) for a variety of pathways. This event promotes recruitment of Akt from the cytoplasm to the cellular membrane where phosphoinositide-dependent kinase-1 (PDK1) phosphorylates the threonine 308 position of Akt. Phosphorylation of the serine 473 position also occurs, although the kinase responsible has not been definitively identified. This step appears to be tightly regulated and may require multiple intracellular messengers including integrin-linked kinase, PDK2 and others. 7 
Upstream inhibitors
An intricate web of inhibitory factors opposing the actions of PI3K and subsequent second messengers control regulation of Akt activation. Most notably, 'phosphatase and tensin homolog deleted on chromosome 10' (PTEN) directly opposes PI3K by removing the 3 0 -phosphate from PI(3,4,5)P 3 . A recently discovered class of phosphatases called SHIP phosphatases also may play a role in controlling levels of PI(3,4,5)P 3 , and thus subsequent Akt activation. However it appears that as SHIP removes the 5-phosphate from PI(3,4,5)P 3 , the resultant PI(3,4)P 2 may still recruit Akt to the plasma membrane. Therefore, PTEN is probably the more important inhibitor. 5 Other recently discovered phosphatases include C-terminal modulator protein and PH domain leucine-rich repeat protein phosphatase, both of which may be significant in Akt regulation. 8 Direct deactivation of Akt is also possible. Protein phophatases (PP1 and PP2a) both govern the regulatory activity of many intracellular messengers including Akt through dephosphophorylation. The complex activity of these regulatory proteins is controlled through cell wall constituents including palmitate, integrin and caveolin. 5 Heat shock protein 90 may oppose the actions of these phosphatases, thereby promoting Akt activity. 9 
Akt downstream effects
Following activation, Akt moves from the cellular membrane to the cytoplasm where it exercises broad control over a variety of intracellular pathways generally supporting survival, proliferation, and other activities necessary for neoplastic disease progression.
Apoptosis and the cell cycle. Cancer cells escape normal biochemical systems regulating the balance between apoptosis and survival. Akt generally acts to promote survival through inhibition of proapoptotic factors and activation of anti-apoptotic factors. For example, the Bcl-2 family of proteins consists of both proapoptotic and anti-apoptotic factors, the balance of which is critical for maintaining cellular homeostasis. Through phosphorylation, Akt inhibits the activity of proapoptotic members such as BAD, BAX and BID while activating antiapoptotic members such as Bcl-xL. [10] [11] [12] Another family of apoptotic regulators is the forkhead family. In general, Akt phosphorylates various members of this family causing translocation from the nucleus to Other biochemical pathways affected include apoptosis-signal-regulating kinase cyclic AMP response element binding protein, and the oncoprotein MDM2. Effects through these include inhibition of jun Nterminal kinase and p53. In addition, Akt may block apoptosis after it has been initiated. For example, Akt can prevent the activation of caspase-9 despite mitochondrial cytochrome c release. 5 Cancer cells also escape normal cellular controls over the cell cycle, generally resulting in increased, deregulated proliferation. Akt activation may promote this process through multiple pathways. Three central regulators of the cell cycle affected by Akt are cyclin D, p21 and p27. Cyclin D is necessary for cyclin-dependent kinase (CDK) activity regulating entry into the cell cycle. p21 and p27 are CDK inhibitors, which oppose cell-cycle progression. Akt phosphorylates and inactivates p21 and p27 thereby eliminating a critical negative regulator of CDK activity and promoting progression through the cell cycle. 5 
Other/multiple pathways
Other necessary cellular characteristics for neoplastic growth include angiogenesis, invasion and metastasis. Biochemical pathways affected by Akt may accomplish these effects with significant changes noted when Akt signaling intensity changes. In addition, three pathways discussed here have multiple or complex effects.
Akt activation may lead to increased angiogenesis through phosphorylation of endothelial nitric oxide synthase and subsequent production of nitric oxide. 13, 14 In addition, Akt is a key activator of the mammalian target of rapamycin (mTOR) which, through stabilization of the hypoxia inducible factor, induces expression of pro-angiogenic genes such as vascular endothelial growth factor. mTOR also promotes cell survival and proliferation through other pathways. Examples of these include activation of p70 ribosomal S6 kinase and inhibition of 4E-BP1, thus promoting ribosomal translation in general, and increased expression of cyclin D, which promotes cellular cycling and proliferation. 5 One cellular pathway affected by Akt with multiple effects is the nuclear factor kappa-B (NFkB) pathway. Akt causes the NFkB binding protein, IkB, to release NFkB, which then translocates to the nucleus where it transcribes multiple genes involved with proliferation, inflammation, cell adhesion, stress response and antiapoptosis. 15 NFkB also increases expression of matrix metalloproteinases, which are frequently elevated in CaP specimens and may play a role in promoting invasion and metastasis.
p53 is a tumor suppressor showing aberrant regulation or mutation in many neoplasms. Akt may play a role in regulating its activity through activation of its binding protein, MDM2. Phosphorylation of MDM2 causes translocation to the nucleus where it inactivates p53 resulting in cell-cycle progression and inhibition of apoptosis. 16 Of special interest in CaP is the observation that Akt can directly phosphorylate the androgen receptor on serine residues at positions 210 and 790. The results of this are controversial with some authors reporting activation while others report suppression of androgen receptor signaling. 17, 18 The reason for this may relate to different cell passage numbers, which is an interesting concept in the context of a rapidly dividing neoplasm. 19 
Alterations of Akt activity in CaP
Increased Akt activity in CaP may be caused by genetic overexpression of Akt or altered expression of its upstream-positive and upstream-negative regulators. In CaP, several such mechanisms are probably active.
Akt overexpression has been demonstrated in CaP. 20 However, the most consistent finding in this disease is the silencing of PTEN and subsequent increase in Akt signaling. 8 PTEN may be lost by deletion, mutation or epigenetic mechanisms. 5 Up to half of the patients CaP tissue specimens show inactivation of PTEN with increasing incidence of this finding in metastatic deposits and AI disease, emphasizing its possible importance in tumor progression. [21] [22] [23] Other genetic overexpression or underexpression of factors upstream of Akt have also been demonstrated in CaP. Various growth factor receptors including the fibroblast growth factor, epidermal growth factor, and insulin-like growth factor are overexpressed in some CaP leading to increased Akt signaling. 5 In addition, PI3K may be overexpressed in CaP, 5 and may be important in the progression to AI disease. 24 Regardless of the molecular mechanisms responsible, the excessive activation of Akt is a poor prognostic factor in CaP. In one report, phosphorylation of Akt was superior to measurements of cellular proliferation and even Gleason grade for predicting biochemical recurrence following radical prostatectomy. 25 Treatments for CaP may also upregulate Akt pathways through activation of cellular stress responses. In CaP specifically, androgen withdrawal may lead to biochemical changes ultimately supporting the emergence of AI disease. Although Akt itself may not be directly involved in causing this transition, some of these pathways signal through Akt. 3, 26 For example, emergence of a neuroendocrine phenotype in CaP may be important in disease progression. Such neuroendocrine cells may convert CaP cells to a dependence on survival signals through Gprotein coupled receptors and growth factor receptors upstream of Akt, bypassing the usual androgen receptor signaling. 26 These data cumulatively provide a rationale for Akt inhibition as a therapeutic paradigm in CaP.
Feedback mechanisms
In light of the pathways and effects of Akt activation discussed above, it seems that Akt inhibition would naturally lead to positive therapeutic benefits in CaP and other neoplasms. Unfortunately, feedback mechanisms inherent in this complex biologic system may cause paradoxical responses to inhibition at various levels of Akt pathways. Two recently discovered feedback mechanisms demonstrate that inhibition of mTOR may, in fact, increase signaling through the Akt pathway. 27 Although not yet demonstrated in vivo, the existence of such complexity demonstrates a clear need for future
therapies at the molecular level. Another factor complicating treatment using Akt inhibitors is one of the most important pathway for normal cellular physiology. It is not yet clear that developing treatment will demonstrate significant efficacy with acceptable levels of toxicity. These facts may lead to the use of Akt inhibition as adjunctive treatment rather than monotherapy.
Akt inhibition as a therapeutic strategy
Data demonstrating the importance of increased Akt signaling pathways in supporting prostatic growth and the neoplastic progression of CaP have stimulated efforts to modulate these pathways through direct and indirect Akt inhibition. In view of the increased activation of Akt during some treatments for CaP, inhibition of Akt may be an important strategy for adjunctive therapy. Multiple inhibitors have been developed using a variety of mechanisms. Inhibition of PDK1 prevents activation of Akt and several effective agents are available (see Table 1 ). Direct inhibition of Akt may target any of the three domains discussed above using competitive, allosteric, pseudosubstrate or other mechanisms (see Table 2 ). Preclinical data on many Akt inhibitors are available and are reviewed in detail elsewhere. [28] [29] [30] [31] Additional data regarding the Akt inhibitory properties of several nutriceuticals is emerging and may prove important in the future. Examples include quercetin, 32 diallyl trisulfide, 33 curcumin 34 and silymarin. 35 This review will be limited to agents for which clinical data are now available.
Selective inhibitors of Akt
Celecoxib
Celecoxib is a potent inhibitor of the inducible enzyme cyclooxygenase-2 (COX-2). By selective inhibition of COX-2 and avoidance of interference with the constitutively active COX-1, it was thought that celecoxib and other selective COX-2 inhibitors might be an effective treatment for inflammatory conditions while avoiding the gastric complications of long-term COX-1 inhibition. Although subsequent testing revealed an association with adverse cardiac outcomes leading to cessation of some ongoing trials, the drug remains on the market.
Celecoxib is currently of interest as preclinical experiments demonstrate significant proapoptotic effects in CaP cell lines. The biochemical activity of the drug is due to prevention of Akt phosphorylation by inhibiting the action of PDK1 27, 36 and this activity is independent of the COX-2 inhibitory effects. 37 In addition, COX-2 inhibitors may have other cellular functions potentiating the apoptotic response. 38 A therapeutic window for celecoxib might exist as the COX-2 enzyme is preferentially expressed in cancer tissue in response to tumor promoters, cytokines and growth factors. 36 However, some experiments show expression of induced COX-2 in CaP to be low if present, especially compared to other epithelial malignancies. 39 Although controversy exists on this point, COX-1 and -2 expression might be higher in the prostate in general regardless of disease processes. 40 Outcomes data up to 20 years ago indicated a cancer chemopreventive effect for anti-inflammatory medications. 41 Large epidemiologic studies have examined this effect in celecoxib in a variety of cancers. 42 Specifically, the rationale for CaP chemoprevention using COX-2 inhibition was reviewed by Basler and Piazza. 43 Although no current clinical chemoprevention data are available, the use of celecoxib as adjunctive therapy merits attention.
A phase II study by Pruthi et al. 44 of celecoxib monotherapy to modify prostate-specific antigen (PSA) doubling time (PSADT) in patients with biochemical relapse following definitive therapy has been reported. Forty patients were enrolled, ninteen of whom had a PSADT of less than 6 months. Following treatment, 36 of 40 patients showed a declining PSADT, and 11 of 40 had their PSA decline with an additional 8 of 40 showing stable PSA values. A following randomized, placebocontrolled trial of this effect was terminated early based on the question of celecoxib safety. An ad hoc analysis of existing data on 78 randomized patients revealed a greater than 200% increase in PSADT in 40% of patients receiving celecoxib compared to 20% receiving placebo (P ¼ 0.08). 45 Recent phase II studies demonstrate the use of celecoxib in combination with docetaxel and zolendronate. 46, 47 Both the studies demonstrated biochemical and objective tumor responses. Another randomized, blinded trial of celecoxib as neoadjuvant therapy before prostatectomy showed activity in the disease. Significant effects on cellular signaling, oxidative stress and cell-cycle regulation were apparent upon blinded in comparison of the pathology specimens. 48 In summary, preclinical data suggest a role for celecoxib in the treatment of CaP. Its apoptotic effects are mediated through inhibition of Akt phosphorylation by antagonism of PDK1. A therapeutic window may allow efficacy and development of derivatives will further refine the specificity of this medication. 
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Perifosine
Phospholipid analogues have been in use as medications for some time. Miltefosine demonstrated activity against many cancers and is still approved in Europe for use in cutaneous lymphoma and cutaneous breast cancer metastases. High rates of gastrointestinal toxicity and low bioavailability led to efforts to discover further modifications of phospholipid analogues with enhanced pharmaceutical potential. Perifosine is a substituted alkylphosphocholine with oral bioavailability. In preclinical experiments, it causes cell-cycle arrest in G 1 /S or G 2 /M, probably through effects mediated by p21 upregulation. 49 These effects appear to occur through inhibition of Akt activation, although the mechanism is incompletely understood. As a phospholipid analogue, perifosine incorporates into the cell wall where it prevents Akt phosphorylation in a PDK1-independent manner. 50 This apparently involves interference with the normal association of PH domains with 3-PI moieties.
Phase I trials established the tolerability of perifosine with most frequent side effects being nausea, vomiting and diarrhea. 51, 52 Two recent phase II trials of perifosine in CaP have been reported. A California Cancer Consortium trial in 25 patients with biochemical recurrence following definitive therapy demonstrated biological and chemical activity, with 23% of patients having a decrease in PSA, although none were 450%. 53 A National Cancer Institute study of 19 men with metastatic AI CaP and average PSA of 180 ng/ml showed no objective or PSA responses, and four patients with PSA stabilization for 12 weeks. 54 Although perifosine is apparently relatively ineffective as monotherapy, the strong preclinical rationale combined with preclinical results showing synergism with other Akt inhibitory drugs suggest the need for more trials examining its role in an adjunctive setting. 55 Phase I trials are already underway for perifosine combined with docetaxel, paclitaxel, gemcitabine and radiation therapy. Future phase II trials at our institution will examine the combination of perifosine with other inhibitors of the Akt pathway in CaP.
Genistein
Genistein is a naturally occurring isoflavone found in soy-based products. Gastric and intestinal hydrolytic reactions convert it to a well-absorbed aglyconic form. In Abbreviation: PH, pleckstrin homology.
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addition, some Asian forms of fermented soy, such as miso, nattou and tempeh, are rich in isoflavone aglycones. Speculation regarding the CaP-inhibitory effects of soy isoflavones exists because of significant epidemiologic differences in CaP incidence mirroring the consumption of, among other things, soy products. 56 Preclinical data demonstrate truly remarkable biochemical characteristics of genistein. In many different cell lines and xenografts, the tyrosine kinase inhibitory characteristics of genistein induce apoptosis, cell-cycle arrest, hinders proliferation, prevents angiogenesis, and blocks androgen and estrogen-stimulated transcription. [56] [57] [58] [59] [60] In addition, studies demonstrate genistein may oppose many cellular survival mechanisms induced by radiation, chemotherapy or androgen deprivation, suggesting the usefulness of this agent as adjunctive therapy. 61, 62 Subsequent analysis of these favorable biochemical changes reveal that many of them are mediated through Akt pathways (see Figure 1 ). For example, NFkB, an upstream regulator of the apoptotic Bcl-2 family and the inhibitors of cyclin dependent kinases, p21 and p27, is activated by many cellular stimuli. Li and Sarkar 63 demonstrated that NFkB activation in PC3 cells is mediated by Akt. In prostate cell lines, experiments at our institution confirm that genistein inhibits activation of Akt, thereby inducing apoptosis similar to other inhibitors of Akt (see Figure 2) . 64 Inhibitors such as LY294002, although completely blocking Akt phosphorylation through PI3K inhibition, are too toxic for human use. Genistein may provide a non-toxic alternative while maintaining sufficient activity to effect a clinical response.
Some of the cellular effects of genistein seen in vitro cannot be initiated at attainable concentrations in humans, even when consuming large amounts of soy. Concentrated aglycone-rich food supplements, such as genistein combined polysaccharide (GCP), may allow higher plasma levels of isoflavones. 58 Recently, a prospective randomized study by Rannikko et al. 65 found that prostate tissue concentrates phytoestrogens including genistein, thus suggesting that plasma concentrations underestimate tissue concentrations by over 50%.
Given the promising preclinical data, studies are ongoing examining the activity of genistein in vivo against CaP. Phase I studies demonstrate general tolerability. 66 A phase II pilot study at our institution examined the ability of GCP to decrease PSA in men with histologically proven CaP. Sixty-two patients with elevated PSA were enrolled. Patients were categorized by prior treatment. Nine, seventeen and six had received prior prostatectomy, radiation therapy, or both, respectively. Fourteen were receiving intermittent hormone ablation and were currently off-cycle. Finally, 16 patients were on an active surveillance protocol. All patients received GCP supplements to be taken orally three times daily for 6 months. Three patients discontinued because of grade 2 diarrhea and seven patients discontinued for personal reasons. Of the 52 remaining patients, 8 had PSA reductions and 1 of them greater than 50%. Interestingly, all of these patients were in the watchful waiting subgroup. In analysis of the responding patients vs others, there did not appear to be any correlation with Gleason score. In addition, estrogenic effects of genistein were probably not the causative factor as testosterone was increased in five responders, decreased in one, and unchanged in two. 67 On the basis of these results, further randomized studies are currently ongoing at our institution. In addition to examination of GCP as monotherapy in patients on watchful waiting protocols, we plan to study GCP in conjunction with androgen deprivation therapy in patients with biochemical relapse following definitive therapy.
Patient selection
Biologic therapies modifying cellular signaling pathways generally show modest responses in most cases. This suggests the need to test such therapies in the adjunctive setting, possibly increasing the response to radiation, chemotherapy or androgen deprivation. 3 For ethical reasons, many existing studies will use Akt inhibitors in conjunction with docetaxel-based chemotherapy. This is a rational strategy as chemotherapy upregulates survival pathways that involve Akt activity. 68, 69 Further efforts to predict patient response to biologic agents by pretreatment measurements of activated pathways through direct tissue or serum analysis may allow individualized treatment. One method involves profiling the entire proteome in patients' serum using matrix assisted laser desorption ionization-time-of-flight mass spectrometry. Multiple bioinformatics analyses of CaP patient serum and normal controls allows for proteomic 'fingerprints' with high discriminatory power. Once such profiles are produced, patients on clinical studies may be compared, allowing characterization of treatment effects on proteome profiles. Examination of the entire proteome may allow more efficient sorting of possible tumor markers. Eventually, exact identification of identified tumor markers is carried out by 2-D electrophoresis or liquid chromatography. 70, 71 In the future, biopsy samples analyzed for expression of such markers may allow ex vivo modeling of diseased pathways. Subsequent study 
Conclusions
Akt inhibition is a rational therapy in CaP treatment. Upregulation of this pathway is involved in initial neoplastic changes in some patients. An increasing number of patients show overexpression or overactivity of Akt as metastatic and AI diseases develop. Preclinical studies demonstrate the importance of this pathway in CaP and the possibility of targeting this pathway with any of an increasing number of inhibitors. In addition to preventing activation by blocking upstream signaling, strategies include allosteric inhibition, small molecule competitive inhibitors, pseudosubstrate inhibitors and others with multiple or unknown activity. Clinical studies with agents known to act through Akt inhibition show some promise. Further studies examining vertical inhibition strategies to block Akt pathways more completely should be performed. More importantly, efforts to extend the activity of current therapeutic options through combination with Akt inhibitors and more accurate methods to select those patients most likely to benefit from Akt inhibition are needed.
